STOCK TITAN

Humana accepts $199M of 2031 notes in tender offers

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Humana Inc. announced final results of cash tender offers for eight series of outstanding notes, with an aggregate purchase-price cap of $1,500,000,000, excluding accrued coupon payments. The offers expired November 16, 2026, and all conditions were satisfied or waived. Humana accepted in full $248,416,000 of 2.150% notes due 2032, $172,052,000 of 3.125% notes due 2029, $388,310,000 of 3.700% notes due 2029, $210,634,000 of 4.875% notes due 2030, $238,532,000 of 1.350% notes due 2027, and $109,877,000 of 3.950% notes due 2027.

For 5.375% notes due 2031, $858,514,000 was tendered and $198,661,000 accepted under an $800,000,000 cap on principal accepted for that series; the stated proration factor was approximately 23.74%. No 5.750% notes due 2028 were accepted from $211,336,000 tendered. Settlement was scheduled for November 18, 2026, when holders of accepted notes were also to receive accrued coupon payments.

Filing Explained

Across the eight series, the offer set consideration from $852.68 to $1,005.77 per $1,000 principal; holders of accepted notes are also due accrued interest, so accepted principal is not the full cash-payment amount.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Aggregate purchase-price cap $1,500,000,000 Excludes accrued coupon payments.
2031 notes series cap $800,000,000 Cap on aggregate principal amount of 5.375% notes due 2031 accepted for purchase.
2031 notes tendered $858,514,000 Principal amount of 5.375% notes due 2031 tendered and not withdrawn.
2031 notes accepted $198,661,000 Principal amount of 5.375% notes due 2031 accepted for purchase.
2031 notes proration factor Approximately 23.74% Applied to the 5.375% notes due 2031.
2028 notes tendered $211,336,000 Principal amount of 5.750% notes due 2028 tendered; none were accepted.
March 2029 notes accepted $388,310,000 3.700% Senior Notes due March 23, 2029; accepted in full.
Tender Cap financial
"up to an aggregate purchase price ... of $1,500,000,000 (the “Tender Cap”)"
A tender cap is the maximum number of shares or maximum total value a buyer will accept in a tender offer, essentially a limit on how much stock the bidder is willing to buy. It matters to investors because if more shares are tendered than the cap allows, the buyer will scale back purchases proportionally, like selling a fixed number of tickets when demand is higher than supply, which affects how many shares each holder can sell and the likely outcome of the offer.
Series Cap financial
"an $800,000,000 cap on the aggregate principal amount ... of the 2031 Notes"
Acceptance Priority Procedures financial
"subject to ... the Acceptance Priority Procedures"
Total Consideration financial
"payable per each $1,000 principal amount"
Total consideration is the full amount of value exchanged in a transaction, including all payments, assets, or benefits involved. It represents what is given up or received in a deal, much like the total price paid when buying a house, covering both the purchase price and any additional costs or benefits. For investors, understanding total consideration helps assess the true scale and value of a transaction.
Accrued Coupon Payment financial
"will also receive an Accrued Coupon Payment"
An accrued coupon payment is the interest earned on a bond that has accumulated since the last payment date but has not yet been paid to the investor. Think of it like interest building up in a savings account that will be paid out later; it reflects the amount the investor is owed for holding the bond during that period. This figure matters because it helps accurately determine the bond’s current value and the investor’s true earnings.
proration factor financial
"at a proration factor of approximately 23.74%"
A proration factor is the percentage used to scale back how many shares or rights each investor receives when demand exceeds the available supply, such as in an oversubscribed offering or dividend distribution. It matters because it determines the actual number of shares an investor will get and the effective price or value per share they end up with — like cutting a limited number of pizza slices among more people than there are slices, so everyone gets a proportional piece.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much of Humana's 2031 notes did HUM accept in the tender offer?

Humana accepted $198,661,000 of the $858,514,000 principal amount of 5.375% notes due 2031 tendered, at an approximately 23.74% proration factor. The series was subject to an $800,000,000 cap on principal accepted.

Did Humana accept the 2028 notes tendered in its HUM debt offer?

No 5.750% notes due March 1, 2028 were accepted. Holders tendered $211,336,000 principal amount of that series, and notes not accepted were to be returned promptly to tendering holders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0000049071false00000490712026-11-162026-11-16


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 17, 2026 (November 16, 2026)
Humana Inc.
(Exact name of registrant as specified in its charter)
Delaware001-597561-0647538
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
101 East Main Street, Louisville, Kentucky 40202
(Address of principal executive offices, including zip code)

(502) 580-1000
(Registrant’s telephone number, including area code)


(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common StockHUMNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 8.01. Other Events.

On November 16, 2026, Humana Inc. issued a press release announcing the pricing terms of the previously announced cash tender offer for certain of its debt securities. Additionally on November 16, 2026, Humana Inc. issued a press release announcing the expiration and results of the cash tender offer. Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:
              Exhibit No.
Description
99.1
Press release issued by Humana Inc. dated November 16, 2026.
99.2
Press release issued by Humana Inc. dated November 16, 2026.
104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL Document).













SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
HUMANA INC.
BY:/s/ John-Paul W. Felter
John-Paul W. Felter
Senior Vice President, Chief Accounting Officer & Controller
(Principal Accounting Officer)
Dated: November 17, 2026



news release
Humana Inc.
101 East Main Street
Louisville, KY 40202
image_0a.jpg
Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
Louisville, KY - November 16, 2026 - Humana Inc. (NYSE: HUM) (“Humana”, “we”, or “our”) today announced the Reference Yield and Total Consideration (as set forth in the table below) to be paid in connection with its previously announced cash tender offers (collectively, the “Offers”) to purchase the outstanding notes described below, in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 9, 2026 (the “Offer to Purchase”).
The Notes offered to be purchased in the Offers, in the order of acceptance priority, are the 2.150% Senior Notes due 2032; 3.125% Senior Notes due 2029; 3.700% Senior Notes due 2029; 4.875% Senior Notes due 2030; 1.350% Senior Notes due 2027; 3.950% Senior Notes due 2027; 5.375% Senior Notes due 2031; and 5.750% Senior Notes due 2028 (collectively, the “Notes” and each a “Series of Notes”) for the consideration described below, up to an aggregate purchase price, excluding the Accrued Coupon Payment (as defined below), of $1,500,000,000 (the “Tender Cap”) subject to proration and the application of the Acceptance Priority Levels set forth in the table below and as further set forth in the Offer to Purchase and the terms and conditions, including, among others, an $800,000,000 cap on the aggregate principal amount to be accepted for purchase of the 5.375% Senior Notes due 2031 (the “2031 Notes”) pursuant to the Offers (the “Series Cap”) and the Acceptance Priority Procedures set forth in the Offer to Purchase. The 2031 Notes may be subject to proration both due to the Acceptance Priority Procedures and the Series Cap such that Humana will only accept for purchase an aggregate principal amount of the 2031 Notes up to the Series Cap. Subject to applicable law, Humana may, but is under no obligation to, eliminate, increase or decrease the Tender Cap and/or the Series Cap. In the event proration is required with respect to a Series of Notes, Humana will multiply the principal amount of each valid tender of such Series of Notes by the applicable proration rate and round the resulting amount down to the nearest integral multiple of the Authorized Denomination, in order to determine the principal amount of such tender that will be accepted pursuant to the applicable Offer. The excess principal amount of Notes not accepted from the tendering Holders will be promptly returned to such Holders, and if this excess principal amount of Notes is less than $1,000, Humana may either accept or reject all such tendering Holders’ validly tendered Notes in its sole discretion. Additionally, Humana may increase the amount of Notes accepted for payment in any Offer by no more than 2% of the outstanding Notes of the applicable Series, as further described in the Acceptance Priority Procedures set forth in the Offer to Purchase, without amending or extending the Offer. The Offer to Purchase and any related documents are referred to herein collectively as the “Tender Offer Documents”. Capitalized terms used but not defined in this press release have the meanings given to them in the Offer to Purchase.
Certain information regarding the Notes and the pricing for the Offers is set forth in the table below.
Series of Notes
CUSIP/ISIN Number (1)
Aggregate Principal Amount OutstandingSeries CapAcceptance Priority LevelReference Security
Reference Yield(2)
Bloomberg Reference Page
Fixed Spread (Basis Points)(3)
Total Consideration(4)
2.150% Senior Notes due February 3, 2032444859BR2 / US444859BR26$487,850,000N/A14.750% UST due 10/31/20314.935%FIT1+50$852.68
3.125% Senior Notes due August 15, 2029444859BK7 / US444859BK72$339,623,000N/A24.875% UST due 10/15/20294.873%FIT1+40$945.78
3.700% Senior Notes due March 23, 2029444859BT8 / US444859BT81$528,559,000N/A34.875% UST due 10/15/20294.873%FIT1+40$965.64
4.875% Senior Notes due April 1, 2030444859BN1 / US444859BN12$500,000,000N/A44.750% UST due 10/31/20314.935%FIT1+50$982.91
1.350% Senior Notes due February 3, 2027444859BQ4 / US444859BQ43$520,488,000N/A54.125% UST due 1/31/20274.171%FIT3+10$993.93
3.950% Senior Notes due March 15, 2027444859BF8 / US444859BF87$429,283,000N/A64.250% UST due 3/15/20274.303%FIT3+10$998.45
5.375% Senior Notes due April 15, 2031444859CA8 / US444859CA81$1,500,000,000$800,000,00074.750% UST due 10/31/20314.935%FIT1+70$989.92
5.750% Senior Notes due March 1, 2028444859BU5 / US444859BU54$493,420,000N/A83.500% UST due 1/31/20284.745%FIT4+50$1,005.77
 
(1)     No representation is made as to the correctness or accuracy of the CUSIP or ISIN numbers listed above.
(2)    Each Reference Yield was determined at 3:00 p.m., New York City time, on November 16, 2026.
(3)     The sum of the Fixed Spread and the Reference Yield is referred to as the “Offer Yield.”



(4)     Represents the total consideration for each Series of Notes (the “Total Consideration”) payable per each $1,000 principal amount of such Series of Notes validly tendered and accepted for purchase in the Offers.
The “Total Consideration” for each Series of Notes payable per each $1,000 principal amount of such Series of Notes validly tendered for purchase is based on the applicable Fixed Spread for such Series of Notes, plus the Reference Yield based on the bid-side price of the applicable Reference Security as quoted on the applicable Bloomberg Reference Page as of 3:00 p.m., New York City time, today, November 16, 2026 (the “Price Determination Date”). In addition to the applicable Total Consideration, Holders whose Notes are accepted for purchase pursuant to an Offer will receive accrued and unpaid interest on those Notes from the last interest payment date with respect to those Notes to, but excluding, the Settlement Date (the “Accrued Interest,” and the payment thereof, the “Accrued Coupon Payment”).
Tenders of Notes of a Series may be validly withdrawn at any time at or prior to 5:00 p.m., New York City time, today, November 16, 2026 (the “Withdrawal Deadline”), but, except as provided in the Offer to Purchase or required by applicable law, may not be validly withdrawn thereafter. The Offers will expire at 5:00 p.m., New York City time, today, November 16, 2026 (the “Expiration Date”). The “Settlement Date” will be the second business day after the Expiration Date and is expected to be November 18, 2026.
The complete terms and conditions of the Offers are set forth in the Tender Offer Documents. Holders are urged to read the Tender Offer Documents carefully. Each Offer is subject to the satisfaction or waiver of certain conditions. If any condition to the Offers is not satisfied or waived, Humana is not obligated to accept for payment, purchase or pay for, and may delay the acceptance for payment of, any tendered Notes, in each case subject to applicable law, and may terminate or alter any or all of the Offers.
Humana has retained Barclays Capital Inc., BofA Securities, Inc., PNC Capital Markets LLC and U.S. Bancorp Investments, Inc. to act as dealer managers (the “Dealer Managers”) for the Offers. D.F. King & Co., Inc. will act as the Tender and Information Agent for the Offers. For additional information, please contact: Barclays Capital Inc. at +1 (833) 410-5757 (toll-free) or +1 (212) 528-7581 (collect), BofA Securities, Inc. at +1 (888) 292-0070 (toll-free) or +1 (980) 388-0539 (collect), PNC Capital Markets LLC at +1 (833) 715-3537 (toll-free) or +1 (212) 878-8946 (collect), or U.S. Bancorp Investments, Inc. at +1 (800) 479-3441 (toll-free) or +1 (917) 558-2756 (collect). Requests for documents and questions regarding the tendering of Notes may be directed to D.F. King & Co., Inc. by telephone at (212) 257-2639 (for banks and brokers only) and (800) 848-3416 (for all others, toll-free), by email at humana@dfking.com or to the Dealer Managers at their respective telephone numbers. Copies of the Offer to Purchase are available at: www.dfking.com/Humana. You may also contact your broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Offers.
Holders of Notes are advised to check with each bank, securities broker or other intermediary through which they hold Notes as to when such intermediary would need to receive instructions from a beneficial owner in order for that Holder to be able to participate in, or withdraw their instruction to participate in the Offers before the deadlines specified herein and in the Offer to Purchase. The deadlines set by any such intermediary and DTC for the submission and withdrawal of tender instructions may be earlier than the relevant deadlines specified herein and in the Offer to Purchase.
This press release is neither an offer to purchase nor a solicitation of an offer to sell the Notes or any other securities. The Offers are made only by and pursuant to the terms of the Offer to Purchase and only to such persons and in such jurisdictions as is permitted under applicable law. The information in this press release is qualified by reference to the Offer to Purchase. None of Humana, the Dealer Managers or the Tender and Information Agent makes any recommendation as to whether Holders should tender their Notes pursuant to the Offers. Holders must make their own decisions as to whether to tender Notes, and, if so, the principal amount of Notes to tender.  

Humana Cautionary Statement
Some of the information included in this press release and the Offer to Purchase may include both historical and forward-looking statements. When used in this press release or the Offer to Purchase (and any documents that we incorporate by reference in the Offer to Purchase), the words or phrases like “expects,” “believes,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events, trends and uncertainties. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, including information set forth under “Risk Factors” beginning on page 17 of the Offer to Purchase, matters described in the Offer to Purchase and in the documents incorporated by reference in the Offer to Purchase, including the “Risk Factors” contained in certain documents incorporated by reference in the Offer to Purchase.
Forward-looking statements should be read in conjunction with the other cautionary statements, risks, uncertainties and other factors identified in our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequently filed reports with the U.S.



Securities and Exchange Commission and elsewhere in the Offer to Purchase. You should read the Offer to Purchase completely and with the understanding that actual future results may be materially different from expectations. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this press release and the Offer to Purchase (and any documents that we incorporate by reference in the Offer to Purchase) might not occur. Our business is highly complicated, regulated and competitive with many different factors affecting results. There may also be other risks that we are unable to predict at this time.
About Humana
Humana Inc. is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.
Contact
Investors: Lisa Stoner - Humana Investor Relations; (502) 580-2652; lstamper@humana.com
Media: Mark Taylor - Humana Corporate Communications; (317) 753-0345; MTaylor108@humana.com




news release
Humana Inc.
101 East Main Street
Louisville, KY 40202
image_0.jpg
Humana Announces Final Results of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
Louisville, KY - November 16, 2026 - Humana Inc. (NYSE: HUM) (“Humana”, “we”, or “our”) today announced the expiration and final results of its previously announced cash tender offers (collectively, the “Offers”) to purchase the outstanding 2.150% Senior Notes due February 3, 2032 (the “February 2032 Notes”), 3.125% Senior Notes due August 15, 2029 (the “August 2029 Notes”), 3.700% Senior Notes due March 23, 2029 (the “March 2029 Notes”), 4.875% Senior Notes due April 1, 2030 (the “April 2030 Notes”), 1.350% Senior Notes due February 3, 2027 (the “February 2027 Notes”), 3.950% Senior Notes due March 15, 2027 (the “March 2027 Notes”), 5.375% Senior Notes due April 15, 2031 (the “April 2031 Notes”) and 5.750% Senior Notes due March 1, 2028 (the “March 2028 Notes” and each such series collectively, the “Notes” and each such series individually, a “Series of Notes”), in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 9, 2026 (the “Offer to Purchase”) and any related documents (collectively with the Offer to Purchase, the “Tender Offer Documents”). Capitalized terms used but not defined in this press release have the meanings given to them in the Offer to Purchase.
The Offers expired at 5:00 p.m., New York City time, on November 16, 2026 (such time and date, the “Expiration Date”). Withdrawal rights for the Offers expired at the Expiration Date, and accordingly, Notes validly tendered in the Offers may no longer be withdrawn except where additional withdrawal rights are required by law.
At the Expiration Date, according to information provided by D.F. King & Co., Inc., the tender and information agent for the Offers (the “Tender and Information Agent”), the aggregate principal amount of each Series of Notes validly tendered and not validly withdrawn pursuant to the Offers and the aggregate principal amount of each Series of Notes accepted for purchase are set forth in the table below.
Series of Notes
CUSIP/ISIN Number (1)
Aggregate Principal Amount Outstanding Prior to Tender OfferSeries CapAcceptance Priority Level
Total Consideration(2)
Aggregate Principal Amount TenderedAggregate Principal Amount Accepted
2.150% Senior Notes due February 3, 2032444859BR2 / US444859BR26$487,850,000N/A1
$852.68
$248,416,000$248,416,000
3.125% Senior Notes due August 15, 2029444859BK7 / US444859BK72$339,623,000N/A2
$945.78
$172,052,000$172,052,000
3.700% Senior Notes due March 23, 2029444859BT8 / US444859BT81$528,559,000N/A3
$965.64
$388,310,000$388,310,000
4.875% Senior Notes due April 1, 2030444859BN1 / US444859BN12$500,000,000N/A4
$982.91
$210,634,000$210,634,000
1.350% Senior Notes due February 3, 2027444859BQ4 / US444859BQ43$520,488,000N/A5
$993.93
$238,532,000$238,532,000
3.950% Senior Notes due March 15, 2027444859BF8 / US444859BF87$429,283,000N/A6
$998.45
$109,877,000$109,877,000
5.375% Senior Notes due April 15, 2031444859CA8 / US444859CA81$1,500,000,000$800,000,0007
$989.92
$858,514,000$198,661,000
5.750% Senior Notes due March 1, 2028444859BU5 / US444859BU54$493,420,000N/A8
$1,005.77
$211,336,000—
 
(1)     No representation is made as to the correctness or accuracy of the CUSIP or ISIN numbers listed above.
(2)    Represents the total consideration for each Series of Notes (the “Total Consideration”) payable per each $1,000 principal amount of such Series of Notes validly tendered and accepted for purchase in the Offers. The Total Consideration for each Series of Notes was determined at 3:00 p.m., New York City time, on November 16, 2026, in the manner described in the Tender Offer Documents.
All conditions to the Offers were satisfied or waived on or prior to the Expiration Date. On the “Settlement Date” of November 18, 2026, Holders whose Notes have been accepted for purchase will also receive an Accrued Coupon Payment. The Notes validly tendered but not accepted for purchase will be returned promptly to the tendering Holders in accordance with the Offer to Purchase.
Based upon information received from the Tender and Information Agent, Humana will accept all tendered February 2032 Notes, August 2029 Notes, March 2029 Notes, April 2030 Notes, February 2027 Notes and March 2027 Notes in full, and will accept the April 2031 Notes at a proration factor of approximately 23.74%. 





Barclays Capital Inc., BofA Securities, Inc., PNC Capital Markets LLC and U.S. Bancorp Investments, Inc. served as dealer managers (the “Dealer Managers”) for the Offers. D.F. King & Co., Inc. served as the Tender and Information Agent for the Offers. For additional information, please contact: Barclays Capital Inc. at +1 (833) 410-5757 (toll-free) or +1 (212) 528-7581 (collect), BofA Securities, Inc. at +1 (888) 292-0070 (toll-free) or +1 (980) 388-0539 (collect), PNC Capital Markets LLC at +1 (833) 715-3537 (toll-free) or +1 (212) 878-8946 (collect), or U.S. Bancorp Investments, Inc. at +1 (800) 479-3441 (toll-free) or +1 (917) 558-2756 (collect). Requests for documents and questions regarding the tendering of Notes may be directed to D.F. King & Co., Inc. by telephone at (212) 257-2639 (for banks and brokers only) and (800) 848-3416 (for all others, toll-free), by email at humana@dfking.com or to the Dealer Managers at their respective telephone numbers. Copies of the Offer to Purchase are available at: www.dfking.com/Humana. You may also contact your broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Offers.
This press release is neither an offer to purchase nor a solicitation of an offer to sell the Notes or any other securities. The Offers were made only by and pursuant to the terms of the Offer to Purchase and only to such persons and in such jurisdictions as is permitted under applicable law. The information in this press release is qualified by reference to the Offer to Purchase.

Humana Cautionary Statement
Some of the information included in this press release and the Offer to Purchase may include both historical and forward-looking statements. When used in this press release or the Offer to Purchase (and any documents that we incorporate by reference in the Offer to Purchase), the words or phrases like “expects,” “believes,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events, trends and uncertainties. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, including information set forth under “Risk Factors” beginning on page 17 of the Offer to Purchase, matters described in the Offer to Purchase and in the documents incorporated by reference in the Offer to Purchase, including the “Risk Factors” contained in certain documents incorporated by reference in the Offer to Purchase.

Forward-looking statements should be read in conjunction with the other cautionary statements, risks, uncertainties and other factors identified in our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequently filed reports with the U.S. Securities and Exchange Commission and elsewhere in the Offer to Purchase. You should read the Offer to Purchase completely and with the understanding that actual future results may be materially different from expectations. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this press release and the Offer to Purchase (and any documents that we incorporate by reference in the Offer to Purchase) might not occur. Our business is highly complicated, regulated and competitive with many different factors affecting results. There may also be other risks that we are unable to predict at this time.
About Humana
Humana Inc. is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.
Contact
Investors: Lisa Stoner - Humana Investor Relations; (502) 580-2652; lstamper@humana.com
Media: Mark Taylor - Humana Corporate Communications; (317) 753-0345; MTaylor108@humana.com



Filing Exhibits & Attachments

5 documents

Keep reading